Table 3 Model input parameters

Stroke recurrent rate

Recurrent rate (0–1 year)

5.90%

-

-

[22]

Recurrent rate (1–2 year)

3.60%

-

-

[22]

Recurrent rate (2–3 year)

2.50%

-

-

[22]

Recurrent rate (3–4 year)

2.20%

-

-

[22]

Recurrent rate (4–5 year)

2.20%

-

-

[22]

Recurrent rate (5–6 year)

2.70%

-

-

[22]

Recurrent rate (6–7 year)

2.70%

-

-

[22]

Recurrent rate (7–8 year)

2.30%

-

-

[22]

Recurrent rate (8–9 year)

2.80%

-

-

[22]

Recurrent rate (after 9 year)

1.60%

-

-

[22]

Death hazard ratios

mRS 0–1

1.00

(1.00-1.20)

lognormal

[19]

mRS 2–5

2.50

(1.70–3.80)

lognormal

[19]

Natural mortality rate (per year)

60–64 years

0.75%

-

-

[20]

65-69years

1.17%

-

-

[20]

70–74 years

2.03%

-

-

[20]

75–79 years

3.56%

-

-

[20]

80–84 years

6.29%

-

-

[20]

85–89 years

10.28%

-

-

[20]

≥ 90 years

16.17%

-

-

[20]

Costs (2021, Chinese Yuan)

Edaravone dexborneol /piece

33.00

33.00-48.80

-

The price from the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2022 edition)

Dl-3-n-butylphthalide/ bottle

116.76

116.76–139.00

-

Hospitalization costs for mRS(0–1)

12613.70

12428.04-12801.87

gamma

[23]

Hospitalization costs for mRS(2–5)

17222.62

16845.03-17606.49

gamma

[23]

Hospitalization costs for mRS(6)

13950.96

12819.43-15155.26

gamma

[23]

Rehabilitation and secondary prevention costs for mRS(0–1)

9264.26

8976.99-9557.81

gamma

[23]

Rehabilitation and secondary prevention costs for mRS(2–5)

14238.24

13460.47-15048.63

gamma

[23]

Mean length of hospitalization

9.90

-

-

[24]

Health Utility

mRS 0–1

0.84

0.66–0.92

beta

[19]

mRS 2–5

0.47

0.24–0.66

beta

[19]

Disutility of recurrent stroke

0.09

0.06–0.11

beta

[25]

Discount rate

5%

0-8%

-

[26]

Transition probability of recurrent stroke

mRS 0–1 to mRS 0–1

39.50%

-

-

Assumption

mRS 0–1 to mRS 2–5

39.50%

-

-

Assumption

mRS 0–1 to mRS 6

21.01%

-

-

[21]

mRS 2–5 to mRS 2–5

78.99%

-

-

Assumption

mRS 2–5 to mRS 6

21.01%

-

-

[21]